tebentafusp,pembrolizumab
immunocore,merck
['tebentafusp', 'melanoma', 'pembro']
 s dr. sarah weiss &amp; colleagues present a phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in hla-a*02:01+ patients with previously treated advanced non-uveal #melanoma (tebe-am). at #asco23 (link below) 
Rutgers Cancer Institute of New Jersey is the state’s only NCI-designated Comprehensive Cancer Center and a leader in patient care and cancer research.